Immunotherapies for Life

Clinical Pipeline Highlights

Product Target Load Indication Development Phase

Pre-clin

Phase I

Phase I/II

Phase II

Phase II/III

B7-H3 131l CNS/Leptomeningeal Metastasis from Neuroblastoma (BTD, ODD and RPDD)
Burtomab B7-H3 131l Desmoplastic Small Round Cell Tumor
B7-H3 124l Diffuse Intrinsic Pontine Glioma
(RPDD)
Burtomab-DOTA B7-H3 177Lu B7-H3 positive LM tumors (Adult)
hu8H9 B7-H3 TBD Solid Tumors (Adult)
Naxitamab GD2 Naked Refractory/Relapsed Neuroblastoma
(ODD and RPDD)
GD2 Naked Osteosarcoma (Pediatric)
(ODD)
hu3F8-BsAb GD2xCD3 Naked GD2 positive solid tumors (Adult)
GD2xCD3 Naked Refractory Neuroblastoma and Ewing's Sarcoma (Pediatric)

BTD (Breakthrough Therapy Designation), ODD (Orphan Drug Designation) and RPDD (Rare Pediatric Disease Designation)

Overview

Y-mAbs Therapeutics, Inc (YmAbs) is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center (“MSK”) under an exclusive worldwide license and research collaboration agreement. YmAbs applies its world-class antibody capabilities to create life-changing immunotherapies for cancer patients of all ages. YmAbs’ innovative product candidates leverage its extensive drug development capabilities and its proprietary protein technology platform – MULTI TAG™.

Mission

Our Mission is to become the world leader in developing better and safer antibody based pediatric oncology products addressing clear unmet medical needs. We will expand into certain adult cancer indications and advance these in collaboration with partners.

Company Highlights

  • YmAbs is a clinical stage biotechnology company specialized in developing novel antibody therapeutics to treat cancer
  • Memorial Sloan Kettering Cancer Center, the world’s largest and oldest private cancer institution, is YmAbs’ scientific collaboration partner and shareholder
  • From MSK, YmAbs has exclusive global rights to two clinical stage antibody programs with a strong validated clinical safety profile, treating more than 1,000 neuroblastoma patients. These programs are today used as “standard-of-care” treatment for patients at Memorial Sloan Kettering Cancer Center
  • Further, YmAbs has licensed a protein Multimerization Technology Platform – MULTI TAG™, incubated and developed at MSK to further enhance the therapeutic effect of antibodies
  • Several ongoing clinical trials significantly improve survival rates for critical unmet medical needs among cancer patients
  • YmAbs has a management team with proven track record and antibody drug development experience as well as expertise in running leading public biopharmaceutical companies